Current stock page

Catalysts

ARGX Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

ARGXargenx SE

Healthcare / Biotechnology

Leader

Strong Relative Position

BullishEdge 9/10
$960.04−$21.29 (−2.17%)

Latest quote

  • Momentum
    74
  • Value
    70
  • Quality
    77
  • Risk resilience
    70
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 25, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 74/100

Momentum 74/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 32.97%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 74/100AIQ Edge 9/10 Strong Relative Position
Beat rate
88%
7 of 8 reported periods
Average surprise
+173.3%
Across covered historical reports
Latest result
+4.8%
Jul 30, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Jul 30, 2026—$7.44$7.80+4.8%$1.66B$2.82B
May 7, 2026—$5.16$5.90+14.3%$1.45B$3.21B
Oct 30, 2025—$4.37$5.18+18.5%$1.28B$947.96M
May 8, 2025—$2.32$2.58+11.2%$861.83M$573.24M
Oct 31, 2024—$0.10$1.39+1290.0%$665.08M$401M
May 9, 2024—-$0.71-$1.04-46.5%$563.91M$329.79M
Oct 31, 2023—-$1.54-$1.25+18.8%$279.81M$510.92M
May 4, 2023—-$2.34-$0.57+75.5%$174.28M$312.69M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
21
Buy
3
Hold
12-month analyst target
$1,168.21
+21.68% versus current price
Based on 24 analyst observations. Targets are estimates, not predictions.
Low target
$861.00
-10.32% vs latest price
Average target
$1,168.21
+21.68% vs latest price
High target
$1,400.00
+45.83% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 25, 2027

Next known earnings or reporting date.

EPS estimate$7.57

Current analyst expectation for the upcoming report.

Revenue estimate$3.35B

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score74

Where event reaction would show up first.

AIQ score74/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
24
Average target
$1,168.21
Target upside
21.68%
Target range
$861.00 - $1,400.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
3
Neutral
2
Negative
0
gurufocus.com · Nov 9, 2026

argenx (ARGX) to Acquire Unnatural Products, Enhancing Immunology Pipeline

On November 09, 2026, argenx SE (NASDAQ: ARGX) announced a definitive agreement to acquire Unnatural Products (UNP), a move that significantly expands its immun

gurufocus.com · Nov 8, 2026

argenx (ARGX) to Present Positive Phase 3 ALKIVIA Trial Data on VYVGART Hytrulo at ACR 2026

On November 08, 2026, argenx SE (NASDAQ: ARGX) announced that the pivotal Phase 3 ALKIVIA trial results demonstrating significant and sustained benefits of its

gurufocus.com · Oct 23, 2026

ARGX Maintained by Evercore ISI Group -- Price Target Raised to $1090

Analyst Rating Update on argenx SE (ARGX) On October 23, 2026, Evercore ISI Group has maintained its 'Outperform' rating on argenx (ARGX) while raising the p

seekingalpha.com · Sep 14, 2026

argenx SE (ARGX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

argenx SE (ARGX) Morgan Stanley 24th Annual Global Healthcare Conference September 14, 2026 9:15 AM EDTCompany ParticipantsKarl Gubitz - Chief Financial...

insidermonkey.com · Aug 22, 2026

argenx SE (ARGX) Won Its Phase 3 Myositis Trial. How Much Does the Subgroup Miss Matter?

argenx SE (NASDAQ:ARGX) delivered a clearly positive headline result from the Phase 3 ALKIVIA trial.

Open full news and sentiment

ARGX Catalysts FAQ

What are the next catalysts for ARGX stock?

ARGX's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move ARGX stock?

Upcoming events that could move ARGX include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could ARGX's next earnings report affect the stock?

ARGX's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive ARGX stock higher?

ARGX could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt ARGX stock?

ARGX could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.